Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Mar 24, 2024; 15(3): 371-374
Published online Mar 24, 2024. doi: 10.5306/wjco.v15.i3.371
High-dose methotrexate and zanubrutinib combination therapy for primary central nervous system lymphoma
Budhi Singh Yadav
Budhi Singh Yadav, Department of Radiotherapy & Oncology, Post Graduate Institute of Medical Education & Research, Chandigarh 160012, India
Author contributions: Yadav BS contributed to concept design, literature review, manuscript writing, revision, final approval.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Budhi Singh Yadav, MD, Professor, Department of Radiotherapy & Oncology, Post Graduate Institute of Medical Education & Research, Regional Cancer Centre, Sector 12, Chandigarh 160012, India. drbudhi@gmail.com
Received: November 23, 2023
Peer-review started: November 23, 2023
First decision: January 12, 2024
Revised: January 13, 2024
Accepted: February 20, 2024
Article in press: February 20, 2024
Published online: March 24, 2024
Core Tip

Core Tip: Primary central nervous system lymphoma is treated with high dose methotrexate induction followed by consolidation with whole-brain radiotherapy or autologous stem cell transplant. Depending on the general condition and disease status of these patients they can be offered maintenance therapy. Zanbrutinib may be offered to these patients for maintaining the response to primary treatment.